NCT05115578View on ClinicalTrials.gov

Remifentanil Effect-site Prediction by Algometry

CompletedOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

May 15, 2020

Study Completion Date

September 30, 2020

Conditions
Conscious Sedation Failure During Procedure
Interventions
DRUG

Remifentanil 1 MG Injection [Ultiva]

Group I TCI effect-site target infusion of 1.5 ng/ml of remifentanil.

DRUG

Midazolam 1 MG/ML Prefilled Syringe

Group II TCI effect-site target infusion of 1.5 ng/ml of remifentanil + 1 mg Midazolam iv

DRUG

Saline solution

Group III Control

DEVICE

Algometry

The algometry technique is used to assess the pain pressure threshold as an analgesic effect of remifentanil concerning Minto's model prediction.

Trial Locations (1)

08035

Ana Abad-Torrent, Barcelona

All Listed Sponsors
lead

Hospital Universitari Vall d'Hebron Research Institute

OTHER

NCT05115578 - Remifentanil Effect-site Prediction by Algometry | Biotech Hunter | Biotech Hunter